Kornimate/medical-research-clean huggingface dataset:
investigating marrow infiltrating lymphocytes in renal cell carcinoma

Conditions: Renal Cell Carcinoma; Urothelial Carcinoma

Summary: the purpose of this research is to collect health-related information as well as bone marrow and blood specimens to determine if a new form of treatment for patients with kidney and bladder cancer may be possible.

this research will collect specimens from the bone marrow and blood to determine if a new treatment for kidney or bladder cancer may be possible. this research study will collect a bone marrow sample as well as a blood sample. participation in the research study will last approximately 60 days which includes time to determine if the patient is eligible to participate in the study, perform the research procedures and follow-up with the patient following the research procedures to determine if they are experiencing any side effects. participation will end approximately 30 days following the bone marrow collection. the bone marrow and blood samples will be collected from all patients in both cohorts only at a single time point, after they have been enrolled on the study.

Eligibility criteria:
inclusion criteria: * age ≥18 years * histologically-confirmed, locally advanced unresectable or metastatic rcc (cohort a) or uc (cohort b). * ecog performance status of ≤1 * adequate bone marrow function: * platelet count ≥ 100 × 10\^9/l * anc ≥ 1.0 ×10\^9/l * lymphocyte count ≥ 0.5 ×10\^9/l * willingness to undergo bone marrow aspiration (bma) exclusion criteria: * prior hematopoietic stem cell transplantation * prior radiation to the pelvic region * use of systemic corticosteroids within 28 days of bma * history of another primary malignancy that has been diagnosed or required therapy within the past 2 years (except completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site). * presence of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring active systemic treatment. if the autoimmune disease has been treated, it must be stable clinically. (hypothyroidism without evidence of grave's disease or hashimoto's thyroiditis is not considered an exclusion criterion.) * pregnant females as documented by a serum beta human chorionic gonadotropin (β-hcg) pregnancy test consistent with pregnancy, obtained within 21 days of bma * infection requiring treatment with antibiotics, antifungal, or antiviral agents within 7 days of bma * known diagnosis of hiv or cmv infection or active viral hepatitis * administration of hematopoietic growth factor support within 14 days before bone marrow aspiration * chemotherapy administration within 28 days of bma * unwilling or unable to comply with the protocol * prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject.

Keywords: marrow infiltrating lymphocytes
resorbable magnesium scaffolds registry

Conditions: Coronary Artery Disease

Summary: the registry follows the esc/eacts guideline and further investigates the clinical performance and short-term safety of rms (resorbable magnesium scaffolds) in a real world setting within the scope of its intended use without further (medical related) exclusion criteria according to their respective instructions for use (ifu).


Eligibility criteria:
inclusion criteria: * according to the ifu exclusion criteria: * according to the ifu

Keywords: registry magmaris coronary artery disease pci resorbable magnesium scaffolds
post-marketing study in femoral popliteal artery of drug coated balloon used for treatment of lower limb ischemia

Conditions: Peripheral Arterial Disease (PAD)

Summary: the objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the drug-coated balloon catheters in the treatment of the superficial femoral artery (sfa) and popliteal arteries (pa).


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old and ≤85 years old 2. rutherford clinical category classification：2-5 3. significant stenosis (≥50%) or occlusions of lesion(s) located in the superficial femoral artery an /or the popliteal artery 4. at least one patent native outflow artery to the ankle free from significant lesion as confirmed by angiography 5. subject has provided written informed consent prior to participation , understands the purpose of this trail and agrees to comply with all protocol-specified examinations and follow-up appointments. exclusion criteria: 1. aneurysms near target lesions or popliteal aneurysms. 2. the guide wire cannot pass smoothly through the target lesion. 3. known allergy to contrast agents, heparin or paclitaxel. 4. patient already enrolled in other investigational (interventional) studies that would interfere with study endpoints or may enroll in other studies after enrollment in this clinical trial. 5. pregnancy or female patient with child bearing potential not taking adequate contraceptives or currently lactating. 6. other comorbidities, which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up.
comparing unimanual and bimanual mirror therapy for upper limb recovery post stroke

Conditions: Cerebral Vascular Accident (CVA); Stroke

Summary: the purpose of this randomized controlled study is to 1. examine the feasibility of a home mirror therapy (mt) program in the nyc metropolitan area; 2. evaluate the effectiveness of home mt versus traditional home exercise program; and 3. evaluate the superiority of unimanual or bimanual mt intervention protocols for chronic stroke subjects with moderate hand deficits. subjects from occupational therapy at the ambulatory care center of nyu langone center with a diagnosis of cerebral vascular accident (cva) or stroke will be divided into three (3) groups: * control group subjects will participate in standard occupational therapy rehabilitation protocol plus a traditional home based exercise program. * experimental group 1 subjects will participate in standard rehabilitation protocol plus unimanual home based mirror therapy program * experimental group 2 subjects will participate in standard rehabilitation protocol plus bimanual home based mirror therapy program.


Eligibility criteria:
inclusion criteria: * first time unilateral stroke \> 3 months post stroke. * cognitively be able to follow direction * cognitively be able to consent to participation in research study * moderate/severe deficits as per the fugl-meyer assessment score from 10-50 and the ability to grasp and release a small towel or washcloth. exclusion criteria: * complex medical problems, that would render the subject unable to participate in an extensive home program * history of pre-existing neurological or psychiatric diseases, orthopedic conditions of the upper limbs, or peripheral nerve injuries that render the subject unable to sit or to move either upper limb * hearing and vision impairments which may impede subjects participation in the home program * perceptual deficits such as apraxia, neglect, or agnosias as per clinical evaluation which may impede subjects participation in the home program * botox injection in affected arm/hand within 3 months * global aphasia that may interfere with understanding instruction for testing or home exercise program.

Keywords: post stroke recovery mirror therapy unimanual mirror therapy bimanual mirror therapy stroke
tamoxifen versus estradiol for unscheduled bleeding in etonogestrel implant users, a randomized pilot trial

Conditions: Vaginal Bleeding

Summary: the purpose of this research study is to evaluate the ability of medicines called tamoxifen or estradiol to prevent annoying vaginal bleeding for arm implant users.

this pilot study compares the use of tamoxifen to estradiol to placebo for seven days once a month up to 5 months in contraceptive implant users starting from the time of implant initiation. participants will record bleeding and satisfaction response in a daily text diary.

Eligibility criteria:
inclusion criteria: * etonogestrel implant users * at time of and/or within 21 days of initial use of etonogestrel implant placement * must agree not to take additional hormonal therapy during the study trial period exclusion criteria: * within 6 months following vaginal or cesarean delivery * within 6 weeks following abortion * currently breastfeeding * positive pregnancy test * contraindications to tamoxifen or estrogen * history of thromboembolism * undiagnosed abnormal uterine bleeding * active cervicitis * bleeding disorder * use of anticoagulation medications * an unwillingness or inability to keep a daily menstrual diary or to follow the study criteria
a study to follow paediatric participants with growth hormone deficiency treated with somapacitan for long term safety information and clinical parameters

Conditions: Growth Hormone Deficiency; Neoplasms; Diabetes Mellitus Type 2

Summary: the aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions. the study population will include 400 paediatric growth hormone deficient participants from the global registry for novel therapies in rare bone and endocrine conditions (globe-reg) treated with once-weekly somapacitan and fulfilling the eligibility criteria of the study. the total duration of the study is planned to 10 years consisting of a 5-year recruitment period in the globe-reg followed by a 5-year follow-up period.


Eligibility criteria:
inclusion criteria: * treated with commercially available somapacitan according to local practice at the discretion of the physician. * primary confirmed diagnosis of growth hormone deficiency as per local practice. * male or female below 18 years of age at the time of signing informed consent in the globe-reg. exclusion criteria: * participants with active malignancy or in treatment for active pre-existing malignancy.
prospective epidemiological study of the prevalence of hla-b*5701

Conditions: Infection, Human Immunodeficiency Virus

Summary: this is a study to determine the prevalence of a genetic marker, hla-b5701, in the uk population. hla-b\*5701 has been strongly associated with the risk of an allergic reaction to a hiv medicine, abacavir. the allergic reaction is known as a hypersensitivity reaction. the study is a prospective study inviting hiv-1 positive patients over the age of 18 years to participate. each participant will complete one study visit. they will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin. they will be asked to give two samples to test for the presence of the genetic marker hla-b\*5701. the two samples are: * a cheek swab * a blood sample in selected centres patients may be asked to provide up to two additional blood samples. these samples will be used to help develop and validate new methods of determining hla-b\*5701 testing.


Eligibility criteria:
inclusion criteria: * hiv-1 infected patients over 18 years of age * patient willing \& able to understand and provide written informed consent exclusion criteria: * none

Keywords: hiv hla-b*5701 abacavir hypersensitivity reaction hiv infection
ultrasound guided penile block vs pudendal block for hypospadias

Conditions: Postoperative Pain

Summary: pain after hypospadias surgery is a challenging issue to solve for anesthesists. many different analgesia techniques were defined in literature for this purpose. the investigators have implemented application of ultrasound guided dorsal penile nerve block into practice for these type of surgeries. main purpose of this study is to compare the efficacy of nerve stimulator guided pudendal nerve block with ultrasound guided dorsal penile nerve block for postoperative analgesia after hypospadias surgery.


Eligibility criteria:
inclusion criteria: * 1 to 10 years of age * asa i-ii * undergoing elective hypospadias surgery exclusion criteria: * infection of the skin at the site of needle puncture area * patients with known allergies to any of the study drugs * coagulopathy * asa iii-iv * patients with neurological disorders

Keywords: postoperative pain ultrasound dorsal penile nerve block pudendal block hypospadias
volumetric integral phase-shift spectroscopy for noninvasive detection of hemispheric bioimpedance asymmetry in acute brain pathology

Conditions: Stroke; Stroke, Acute; Ischemic Stroke; Hemorrhage; Clot (Blood); Brain; Subarachnoid Hemorrhage; Cerebral Infarction; Cerebral Hemorrhage; Cerebral Stroke; Intracerebral Hemorrhage; Intracerebral Injury

Summary: the purpose of this study is to assess the ability of the fluids monitor to detect hemispheric bioimpedance asymmetry associated with acute brain pathology in patients presenting with suspected acute ischemic stroke (ais).

a prospective non-significant-risk (nsr) multi-site observational study. this study will examine up to 318 subjects undergoing evaluation for acute brain pathology who directly arrive at, or are transferred to, the participating sites.

Eligibility criteria:
inclusion criteria: 1. must be at least 18 years of age. 2. being evaluated for acute ischemic stroke. 3. able to safely wear the study device for up to 2 minutes per reading. 4. have nihss performed before before study device monitoring. 5. must be able to provide written informed consent (either self or via an lar) at any point during the hospital stay, or if unable to provide such consent, must have permission granted by the governing irb to enroll in the study (i.e., waiver of consent). exclusion criteria: 1. known or suspected traumatic brain injury, either closed or penetrating. 2. contraindication to neuroimaging, such as a contrast allergy, or other condition that prohibits ct, mri, and/or angiography. 3. presence of any implanted electro-stimulating devices in the head and neck. 4. presence of any large metallic craniofacial implants, such as bone fixation plates, mesh, et cetera. (note that small metallic objects, such an aneurysm coils, are acceptable.) 5. presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device. 6. under arrest or otherwise in custody. 7. inability to wear the investigational device (skin lesions on scalp, previous intracranial surgeries, etc.). 8. pregnant or nursing. 9. any other condition, which in the judgment of the pi would prevent the patient from completing the study or tolerating monitoring sessions and brain imaging, such as mental illness, severe agitation, or hemodynamic instability.
comparison of efficacy of different drug combinations in acute sciatica

Conditions: Sciatica Acute; Sciatica

Summary: the goal of this clinical trial is to compare different combinations of diclofenac with diclofenac monotherapy in acute sciatica. the main questions it aims to answer are: * does the combination of diclofenac plus codeine better than diclofenac monotherapy for treating severe pain of sciatica * does the combination of diclofenac plus lacosamide better than diclofenac monotherapy for treating severe pain of sciatica participants will be asked to mark their pain intensity on a visual analog scale and fill oswestry disabilit index questionnaire,treatments they'll be given includes either 1. diclofenac monotherapy 2. diclofenac plus codeine 3. diclofenac plus lacosamide researchers will compare the above three groups to see if severity of pain and disability lowered after medication

musculoskeletal conditions are the most common cause of intense long-term pain, physical disability and early deaths. they affect hundreds of millions of people of all ages irrespective of social strata globally. lumbar radicular pain (lrp), commonly referred to as "sciatica" is a relatively common musculoskeletal disorder. objective of the study is to evaluate the efficacy of different drug combinations with diclofenac for the treatment of acute sciatica. the design of the study is single-center, clinical trial with three arms. (single blinding). one hundred and twenty patients were enrolled in this study between september 2021 and july 2022 at the pharmacology department of islamic international medical college (iimc) rawalpindi in collaboration with the neurosurgery department, of shaheed zulfiqar ali bhutto medical university (szabmu) pakistan institute of medical sciences (pims) islamabad. informed verbal and written consent was taken from all patients. 40 patients were in the diclofenac (50 mg) plus placebo group, 40 in the codeine (30 mg) plus diclofenac (50 mg) group and 40 in lacosamide (50 mg) plus diclofenac (50 mg) group. patients were followed up at day 5, 10 and 15 to assess change in pain intensity and functional disability. the use of rescue analgesia was also assessed at the final day of outcome

Eligibility criteria:
inclusion criteria: * patients diagnosed with acute sciatica with or without lower back pain * 18-70 years of age reporting acute pain due to sciatica exclusion criteria: * pregnant or breastfeeding mothers. * history of asthma or allergy to anti-inflammatory drugs. * mentally handicapped or terminally ill patients. * age less than 18 years or above 70 years * patients with herniated, sequestrated, or prolapsed discs waiting for surgery. * patient having an active ulcer (gastric or duodenal) or bleeding from the stomach or bowel. * patients already taking an anti-depressant medication, a medication for neuropathic pain, an anticonvulsant, or a sedative and unable to cease the medication

Keywords: acute sciatica, codeine, diclofenac, efficacy, lacosamide
endomina as an aid for endoscopic full thickness resection

Conditions: Submucosal Tumor of Intestine

Summary: the concept of natural orifice transluminal endoscopic surgery (notes) (1) has evolved to endoscopic full thickness resection (eftr). it represents innovation in technique that allows endoscopists to advance further into the endoscopic surgical space. eftr has transformed the ability to tackle subepithelial tumors (sets) and early mucosal neoplasm that are not amenable to classic esd technique, enhance the staging accuracies for marginal lesions, and even increase the diagnostic capabilities for infiltrative disorders. thus far, multiple methods have been described to perform eftr, including nonexposed and exposed techniques, with the closure occuring before resection or after resection, respectively (2). early comparative studies show no difference between the two methods (3). however, the procedures themselves are limited by the current tools available and by described techniques to achieve resection. investigators are described here a novel non-exposed technique, with closure before resection, using the endomina device.


Eligibility criteria:
inclusion criteria: 1. lesion untreatable with standard technique. 2. age between 18-65 years; 3. must be able to comply with all study requirements for the duration of the study as outlined in the protocol. this includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations; 4. must be able to understand and be willing to provide written informed consent; 5. must live within 75 km of the treatment site; exclusion criteria: 1. achalasia and any other esophageal motility disorders (for upper gi lesion) 2. severe esophagitis (for upper gi lesion) 3. gastro-duodenal ulcer (for upper gi lesion) 4. severe renal, hepatic, pulmonary disease or cancer; 5. gi stenosis or obstruction; 6. pregnancy, breastfeeding or willing to become pregnant in the coming 18 months; 7. anticoagulant therapy; 8. impending gastric surgery 60 days post intervention (upper gi); 9. currently participating in other study
video-tumorboard plus

Conditions: Malignant Melanoma; Telemedicine

Summary: in weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. by further developing and optimizing the cccs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.


Eligibility criteria:
inclusion criteria: * the study includes adult, external patients who, according to the certification requirements of the german cancer society, should be presented to the cccs in a tumor board . inclusion criteria for patients: * minimum age 18 years * consent to participate in the study (signing of patient consent) should be presented in vtb+ according to the doctor, based on the disease/diagnosis, especially in the case of: * malignant melanoma from stage iib * malignant melanoma and stage shift/recurrence o extracutaneous melanoma o cutaneous lymphoma from stage ib o problem cases with malignant, epithelial tumors (bcc, scc) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. ulcus rodens, ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including merkel cell carcinoma, dfsp, mfh, leiomyosarcoma, s., kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: an external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the ccc) . this also applies to patients who are only seen once at the vtb. in this case, revenue/cost aspects and the dkg requirement are ignored. this means that so-called external patients can also be treated at the center, including initiation of therapy. the decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved. inclusion criteria for external doctors: * has a medical license * has dermatological patients who are eligible to be presented in the vtb+ exclusion criteria: patients will be excluded from the study if they meet the following criteria: * linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy. * no consent to participate in the study (patient consent) or withdrawal of consent during the course of the study in addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.

Keywords: malignant melanoma telemedicine